Our pharmacogenomic analysis revealed that MS4A6A-high GBM samples displayed greater predicted sensitivity to mTORC1/2 and ERK1/2 inhibitors (AZD8055, SCH772984). The gene discussed is MAPK3; the disease is glioblastoma.